The Role of Pharmacoeconomics in Disease Management
- 18 Downloads
In the US, managed-care organisations (MCOs) have turned to pharmacy benefit management (PBM) companies to contain costs and provide total disease management packages. The demand for pharmacoeconomic research and information by purchasers of healthcare has contributed to the growth of PBM companies and to recent acquisitions by pharmaceutical manufacturers. PBMs influence prescribing via formulary management and drug utilisation review (DUR). Formularies are generally open, and pharmacoeconomic data contribute to formulary management decisions. Prospective and concurrent DURs used in hospitals can soon be integrated into community pharmacy, as PBMs obtain integrated online information about prescribing. PBM prescription databases are used as as educational tools for physicians, providing drug utilisation data, formulary compliance, generic prescribing rates, and guidelines for pharmacotherapy for particular conditions. They can also evaluate medication regimens for patients with particular problems such as drug-drug interactions. However, PBM databases typically lack patient diagnostic, outcome and medical claim data. PBMs will be better placed to move from medication management to disease management when they can obtain these data and link them appropriately to their own prescribing and physician databases.
KeywordsDisease Management Disease Management Programme Pharmacoeconomic Data Drug Utilisation Review Pharmacy Benefit Management
Unable to display preview. Download preview PDF.
- 1.Anon. Market Letter 18 July 1994; 3Google Scholar
- 2.The expanding role of PBMs. Business and Health (Special report) 1995; 3: 6–11Google Scholar
- 5.American Society of Hospital Pharmacists. ASHP statement on the formulary system. Am J Hosp Pharm 1986; 43: 2839–42Google Scholar
- 7.Gray M. Whither PBMs? Pharmaceutical Times Feb 1995; 29Google Scholar
- 12.Anon. The EDI revolution. Business and Health (Special report) 1995; 13 (No. 3) Suppl. B: 22–4Google Scholar
- 13.Glass H. Quality of life and formularies. Scrip Magazine 1995; 38: 45–7Google Scholar
- 14.Anon. Which diseases are appropriate for disease management? PharmacoResources 27 May 1995; 29: 15Google Scholar
- 16.National Asthma Education and Prevention Program. Role of the pharmacist in improving asthma care. Am J Health-Systems Pharmacy 1995; 52: 1411–16Google Scholar
- 17.Anon. Pharmacy risk-sharing promotes saving. Business and Health (Special report) 1995; 13 (No. 3) Suppl. B: 18–21Google Scholar
- 18.Anon. Health care reform. Business and Health (Special report) 1995; 13 (No. 3) Suppl. C: 9Google Scholar